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Purpose: Using FibroScan® to obtain a reliable liver stiffness measurement 
(LSM) may require more than 10 valid measurements (VMs), according to the 
manufacturer’s recommendations. However, this requirement lacks scientific evi-
dence in support thereof. We investigated the minimal number of VMs required 
to assess liver fibrosis without significant loss of accuracy in patients with chronic 
hepatitis B (CHB) and C (CHC) and predictors of discordance between LSM and 
liver biopsy (LB). Materials and Methods: Between January 2005 and Decem-
ber 2009, we prospectively enrolled 182 patients with CHB and 68 patients with 
CHC who were to undergo LB and LSM before starting antiviral treatment. Only 
LSMs with at least 10 VMs were considered reliable. The Batts and Ludwig scor-
ing system was used for histologic assessment. Results: The mean age and body 
mass index were 46.0 years and 23.4 kg/m2 in patients with CHB and 49.7 years 
and 23.1 kg/m2 in those with CHC, respectively. The median elasticity scores 
from the first 3, first 5, and all VMs taken significantly predicted fibrosis stages 
≥F2 and F4 (all p<0.05) without significant differences (all p>0.05 by DeLong’s 
method). Alanine aminotransferase (ALT) was the only predictor of discordance 
in fibrosis stage as estimated by the median elasticity score from the first 3 VMs 
and by LB in patients with CHB, whereas no significant predictor was identified 
in those with CHC. Conclusion: After comparison of patients who had more than 
10 valid measurements for LSM, three VMs may be enough to assess liver fibro-
sis using LSM without significant loss of accuracy in patients with CHC and pa-
tients with CHB. However, ALT should be considered when interpreting LSM for 
patients with CHB.
Key Words:    Chronic viral hepatitis, chronic hepatitis B, chronic hepatitis C, fi-
broscan, liver stiffness measurement, transient elastography
INTRODUCTION
Liver stiffness measurement (LSM) using FibroScan® has been considered as a rap-Hui Won Jang, et al.
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(75.8%) patients received LSM on the same day as LB, 
while 67 patients (24.2%) received LSM shortly before LB 
(median, 6 days; range, 2-10).
Exclusion criteria were as follows: 1) evidence of decom-
pensated liver cirrhosis, such as a history of variceal bleed-
ing, ascites, hepatic encephalopathy, or Child-Pugh class B/
C at the time of LSM;11 2) previous history of antiviral treat-
ment; 3) coexisting hepatocellular carcinoma; 4) coinfec-
tion with hepatitis D or human immunodeficiency virus; 5) 
alcohol ingestion in excess of 20 g/day for men and 30 g/
day for women in excess of 5 years; 6) insufficient LB 
quality (LB length <15 mm);12 7) fewer than 10 VMs (n=9); 
8) LSM failure (no valid shot, n=1); and 9) right-sided heart 
failure.13 By these criteria, we excluded 27 patients (8 pa-
tients with fewer than 10 VMs, 16 with insufficient LB 
quality, 1 with hepatocellular carcinoma, 1 with LSM fail-
ure due to ascites, and 1 with fewer than 10 VMs and insuf-
ficient LB quality) and enrolled 250 for final analysis (182 
with CHB and 68 with CHC). The characteristics of the pa-
tients excluded are shown in Table 1. There were no differ-
ences in baseline characteristics between the 182 enrolled 
patients and the 9 patients excluded due to fewer than 10 
VMs (all p>0.05). Among the 9 patients with fewer than 10 
VMs, 7 patients had 3-9 VMs and 5 (71.4%) out of these 7 
patients showed the same fibrosis grade as assessed by 
LSM and LB. Forty IU/mL was defined as the upper limit 
of normal (ULN) of alanine aminotransferase (ALT).
The study protocol complied with ethical guidelines of 
the 1975 Declaration of Helsinki. Each participant or a re-
sponsible family member gave their written informed con-
sent after the possible complications of LB had been fully 
explained. The independent institutional review board of 
our institute (Severance Hospital) approved this study.
Liver stiffness measurement
LSM using FibroScan® generates an elastic wave using a vi-
brator applied to the intercostal spaces at the level of the right 
lobe of the liver and measures the propagation velocity of the 
shear wave, which is directly related to liver stiffness.14 In the 
present study, a single experienced operator, who was blind-
ed to patients’ clinical data and LB results, performed all 
LSMs. Success rate was calculated as the number of VMs di-
vided by the total number of measurements. Liver stiffness 
was expressed in kilopascals (kPa). IQR was defined as an 
index of intrinsic variability of LSM corresponding to the in-
terval of LSM results containing 50% of the valid measure-
ments between the 25th and 75th percentiles. The median 
id and noninvasive method to assess liver fibrosis in patients 
with chronic hepatitis B (CHB) and chronic hepatitis C 
(CHC).1-3 Results to date show that LSM can help physi-
cians decide treatment strategies, predict prognosis, and 
monitor disease progression or regression in patients with 
chronic liver disease.4 Although LSM is generally reliable, 
three conditions are recommended by the manufacturer to 
ensure its reliability: more than 10 valid measurements 
(VMs), successful measurements in more than 60% of all 
measurements taken,1,2 and an interquartile range/median 
value (IQR/M) less than 0.3.5,6 However, the manufacturer’s 
recommendations are not based on scientific evidence, and 
recent studies have challenged the influence of these param-
eters on LSM accuracy.7-9
Although the influences of success rate and IQR/M on 
LSM accuracy have been tested in several previous stud-
ies,7,8,10 the optimal number of VMs has not been elucidat-
ed. Accordingly, if fewer than 10 VMs were sufficient for a 
reliable LSM, and if the currently recommended number of 
VM (more than 10) was overestimated, then some LSM re-
sults based on fewer than 10 VMs might have been discard-
ed, even though they accurately reflected the status of liver 
fibrosis. Furthermore, repeated trials to obtain more than 10 
VMs might decrease the overall success rate due to accumu-
lation of unsuccessful measurements, causing these LSM re-
sults might have been needlessly discarded as well. There-
fore, uncertainty with the optimal number of VMs may 
limit further application of LSM and deprive some patients 
of the benefits this noninvasive device provides in diagnos-
ing significant liver diseases.
Hence, we investigated the minimal number of VMs re-
quired to assess liver fibrosis without significant loss of ac-
curacy in patients with either CHB or CHC and the predic-
tors of discordance between LSM and liver biopsy (LB).
MATERIALS AND METHODS
　　　
Patients
Between January 2005 and December 2009, we enrolled 
206 consecutive patients with CHB and 71 patients with 
CHC who were to undergo LB and LSM before starting 
antiviral treatment. We defined CHB by the presence of de-
tectable hepatitis B virus surface antigen for more than 6 
months and the presence of HBV DNA, and we defined 
CHC by the presence of detectable serum anti-hepatitis C 
virus antibodies and HCV RNA. Two hundred and ten Valid Shot Number to Assess Liver Fibrosis by FibroScan®
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Asian studies which reported on the performance of LSM in 
patients with CHB,20,21 choosing the LSM cutoff values from 
Chan, et al.20 as a reference because they used a larger sam-
ple size (n=161 vs. 88). Since the article by Chan, et al.20 did 
not include the LSM cutoff value for fibrosis stage ≥F2, we 
obtained it from them directly.8 Finally, the optimal cutoff 
LSM values for fibrosis stages ≥F2, ≥F3 and F4 for our study 
population with CHB were 6.0, 8.4 and 9.0 kPa, respectively.
For patients with CHC, Stebbing, et al.19 reported LSM 
cutoff values in their meta-analysis of European studies; 
however, the value for fibrosis stage ≥F3 was absent. Fur-
thermore, the cutoff values in their analysis may potentially 
be biased with the preponderance of patients with high BMI 
in the studies included.19 It is plausible that BMI influences 
LSM cutoff values.6 Thus, we consulted two external stud-
ies, conducted in Japan, on the performance of LSM in 
Asian patients with CHC.22,23 One of these, Takeda, et al.,22 
did not provide optimal LSM cutoff values, so we excluded 
it. We eventually used the cutoff values presented by Nitta, 
et al.23 as our reference. For our study population with 
CHC, the optimal LSM cutoff values for fibrosis stages 
≥F2, ≥F3, and F4 were 7.1, 9.6, and 11.6 kPa, respectively. 
Statistical analysis
The patient characteristics are presented as the mean±standard 
deviation or n (%) as appropriate. The independent t-test or 
Mann-Whitney U-test was used for continuous variables, 
while the χ2 test or Fisher’s exact test was used for categori-
cal variables. The performance of LSM in predicting signif-
icant fibrosis (≥F2) and cirrhosis (F4) using median elastic-
ity scores from the first 3, first 5, and all VMs taken was 
value was considered representative of the elastic modulus of 
the liver. Only LSMs with at least 10 VMs were considered 
reliable. Any LSM that did not meet these criteria of reliabili-
ty was excluded.
Liver histology
LB specimens were fixed in formalin and paraffin-embed-
ded. Four-micrometer sections were stained with hematoxy-
lin and eosin as well as Masson trichrome. All liver tissue 
samples were evaluated by an experienced hepatopatholo-
gist who was blinded to patients’ clinical data and LSM re-
sults. LB specimens shorter than 15 mm were considered 
unsuitable for fibrosis assessment and were excluded from 
analysis.
Liver histology was evaluated semiquantitatively using 
the Batts and Ludwig15 scoring system. Steatosis was cate-
gorized by visual assessment as S0 (nonsignificant, <5%), 
S1 (mild, 5-33%), S2 (moderate, 34-66%), and S3 (severe, 
>66% of hepatocytes with fat deposits).16
Selection of reference LSM cutoff values
After establishing a minimal number of VMs required for a 
reliable LSM, we aimed to identify predictors of discordance 
in fibrosis stage as estimated by the median elasticity score, 
which was based on the minimal VM requirement, and by 
LB. Therefore, we sought external reference cutoff values 
for LSM from the literature.
We found three meta-analyses on LSM.17-19 However, 
most studies included in these meta-analyses involved Euro-
pean patients with CHC and higher body mass indices (BMI) 
than found in Asian populations. Thus, we selected two 
Table 1. Baseline Characteristics
Variables
Chronic hepatitis B (n=206) Chronic hepatitis C (n=71)
Enrolled
n=182 (88.3%)
Excluded
n=24 (11.7%) p value Enrolled
n=68 (95.8%)
Excluded
n=3 (4.2%) p value
Age (yrs)   46.0±11.6 50.8±8.6 0.050    49.7±11.5   58.2±11.1 0.117
Male 123 (67.6) 11 (45.8) 0.015  27 (39.7) 2 (66.7) 0.999
Body mass index (kg/m
2) 23.4±2.8 24.2±3.1 0.227  23.1±3.2 24.0±1.5 0.507
Biopsy length (mm) 17.5±2.7 12.1±5.3 <0.001 17.2±2.7 10.6±3.8 <0.001
Albumin (g/dL)   4.3±0.6   3.8±0.6 <0.001   4.4±0.4   4.5±0.3 0.312
Total bilirubin (mg/dL)   0.9±1.2   0.9±0.5 0.952    0.7±0.4   0.8±0.2 0.710
ALT (IU/L)   58.3±64.3   50.8±54.1 0.576    53.2±59.8   53.0±54.1 0.995
Platelet count (10
3/mm
3) 172.0±66.6   314.2±835.5 0.403  201.6±64.5  154.8±54.9 0.119
Prothrombin time (%)   91.9±10.1   87.1±13.7 0.104  97.5±7.0 100 0.419
Spleen size (cm) 10.3±1.8 10.3±1.6 0.966    9.6±1.5   9.7±1.2 0.894
LSM value (kPa)   14.9±12.3   17.3±11.9 0.363   10.4±11.2   8.9±5.5 0.773
ALT, alanine aminotransferase; LSM, liver stiffness measurement; kPa, kilopascal.
Variables are expressed as the mean±SD or n (%).Hui Won Jang, et al.
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Baseline LSM data 
The baseline LSM data are summarized in Table 2. The 
mean number of VMs acquired was 11.1 in patients with 
CHB and 11.2 in those with CHC. Patients with CHB and 
CHC did not differ significantly in the mean of median 
elasticity scores obtained using the first 3, first 5, and all 
VMs taken (all p>0.05).
Liver histology and the range of LSM according to 
fibrosis stage
Distributions of fibrosis stage, activity grade, and steatosis 
are listed in Table 3. Significant fibrosis (≥F2) was observed 
in 167 (91.7%) patients with CHB and 46 (67.6%) with 
CHC. Only two (1.1%) of 182 patients with CHB and two 
(2.9%) of 68 patients with CHC showed moderate steatosis 
(S2), whereas most patients (80.2% of CHB and 80.9% of 
CHC) showed nonsignificant steatosis (S0). 
The median LSM values and ranges according to fibrosis 
stages are shown in Fig. 1. The median LSM value was 5.4 
kPa (range, 3.7-15.3) in F0F1 fibrosis stage; 6.8 kPa (range, 
4.1-58.2) in F2; 8.1 kPa (range, 5.7-11.8) in F3; and 14.3 kPa 
(range, 5.1-73.5) in F4 in patients with CHB. LSM values 
were significantly different between stages F3 and F4 in pa-
tients with CHB (p<0.001). In those with CHC, the median 
LSM value was 4.5 kPa (range, 3.3-10.2) in F0F1; 6.3 kPa 
(range, 3.5-42.2) in F2; 10.4 kPa (range, 7.1-17.3) in F3; and 
26.6 kPa (range, 11.5-67.8) in F4. LSM values were signifi-
cantly different between stages F01 and F2 and between stag-
es F3 and F4 in patients with CHC (p=0.026 and p=0.048, re-
spectively).
Among patients with fibrosis stage F2, one patient with 
CHB and another one with CHC had extremely high LSM 
values (58.2 kPa and 42.2 kPa, respectively). Both of these 
patients had activity grade 4, high ALT (603 IU/L and 187 
IU/L, respectively), and total bilirubin levels of 9.2 mg/dL 
and 2.7 mg/dL, respectively.
assessed using the receiver operating characteristic (ROC) 
curves and the area under the ROC (AUROC) curve, which 
is similar to a previous study.9 Performance values were 
compared using the method presented in DeLong, et al.24 
The optimal ALT cutoff values were determined to maxi-
mize the sum of sensitivity (Se) and specificity (Sp). As 
LSM and LB results are too variable to determine small dif-
ferences,12 we defined “discordance” as a difference greater 
than or equal to two fibrosis stages between LB and LSM. 
Binary logistic regression analysis was used to identify pre-
dictors of discordance in fibrosis stages as estimated by the 
median elasticity score from the identified minimal number 
of VMs and by LB. A two-sided p value of less than 0.05 
was considered significant. All statistical computations were 
performed with SPSS software version 12.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
 
Baseline characteristics
The baseline characteristics of all patients are presented in 
Table 1. The proportion of males, biopsy length, and serum 
albumin for the 24 excluded patients with CHB were sig-
nificantly lower than the 182 enrolled patients overall (all 
p<0.05). Among those with CHC, 3 excluded patients dif-
fered from the 68 enrolled patients in having only a signifi-
cantly smaller biopsy length (p<0.001).
The mean age and BMI of the 182 enrolled patients with 
CHB were 46.0 years and 23.4 kg/m2 (Table 1), which are 
similar to those of a previous study by Chan, et al.20 (45 
years and 24 kg/m2). In contrast, the mean age and BMI of 
the 68 enrolled patients with CHC was 49.7 years (median 
52, range 18-76) and 23.1 kg/m2. The median age of our 
study population with CHC was slightly lower than that of 
a previous study by Nitta, et al.23 (57 years).
Table 2. Baseline LSM Data 
Variables Chronic hepatitis B (n=182) Chronic hepatitis C (n=68)
Total number of shots 11.1±2.0 11.2±1.7
    Success rate (%) 96.1±8.3 94.5±9.0
    Interquartile range (kPa)   2.5±2.8   1.7±2.3
    Interquartile range/median (kPa)   0.15±0.08   0.16±0.10
Median LSM values
    Up to the first 3 VMs (kPa)   14.9±12.2   10.5±11.2
    Up to the first 5 VMs (kPa)   14.9±12.2   10.5±11.2
    All VMs (kPa)   14.9±12.3   10.4±11.2
LSM, liver stiffness measurement; VMs, valid measurements; kPa, kilopascal.
Variables are expressed as the mean±SD.Valid Shot Number to Assess Liver Fibrosis by FibroScan®
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the first 3 VMs taken and by LB (Table 5). Using the LSM 
cutoff values from Chan, et al.,20 discordances were identi-
fied in 28 (15.4%) patients with CHB. Using the cutoff val-
ues from Nitta, et al.,23 we found discordance in 4 (5.9%) 
patients with CHC.
ALT remained as the only independent predictor of discor-
dance in patients with CHB [p=0.006; hazard ratio (HR), 
1.010; 95% confidence interval (CI), 1.003-1.017], whereas 
no independent predictor was identified for patients with 
CHC.
DISCUSSION
LSM is generally considered reliable when more than 10 
Performance of LSM in predicting significant fibrosis 
(≥F2) and cirrhosis (F4)
Table 4 and Fig. 2 show the diagnostic performance and 
corresponding ROC curves for predicting fibrosis stages 
≥F2 and F4 using LSM. The median elasticity scores from 
the first 3, first 5, and all VMs taken significantly predicted 
fibrosis stages ≥F2 and F4 (all p<0.05) and did not differ 
significantly in AUROC values (all p>0.05).
Predictors of discordance between LSM and LB
Since the performance values for predicting fibrosis stages 
≥F2 and F4 did not differ using the median elasticity scores 
from the first 3, first 5, and all VMs taken, we used multi-
variate analysis to identify predictors of discordance in fi-
brosis stage as estimated by the median elasticity score from 
Table 3. Liver Histology
Chronic hepatitis B (n=182) Chronic hepatitis C (n=68)
Fibrosis stage
     F0F1  15 (8.3)    22 (32.4)
     F2    37 (20.3)    28 (41.1)
     F3    19 (10.4)      7 (10.3)
     F4  111 (61.0)    11 (16.2)
Activity grade
     A0 0 (0) 0 (0)
     A1    9 (4.9)    1 (1.5)
     A2    69 (37.9)    14 (20.6)
     A3    96 (52.7)    52 (76.4)
     A4    8 (4.5)    1 (1.5)
Steatosis
     S0  146 (80.2)    55 (80.9)
     S1    34 (18.7)    11 (16.2)
     S2    2 (1.1)    2 (2.9)
     S3 0 (0) 0 (0)
Variables are expressed as n (%).
Fig. 1. Distribution of LSM values according to fibrosis stage in patients with CHB (A) and CHC (B). The median LSM value was 5.4 kPa (range, 3.7-15.3) in fi-
brosis stage F0F1; 6.8 kPa (range, 4.1-58.2) in F2; 8.1 kPa (range, 5.7-11.8) in F3; and 14.3 kPa (range, 5.1-73.5) in F4 in patients with CHB. In those with CHC, it 
was 4.5 kPa (range, 3.3-10.2) in F0F1; 6.3 kPa (range, 3.5-42.2) in F2; 10.4 kPa (range, 7.1-17.3) in F3; and 26.6 kPa (range, 11.5-67.8) in F4. LSM, liver stiffness 
measurement; CHB, chronic hepatitis B; CHC, chronic hepatitis C; kPa, kilopascal.   
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dict discordance of more than 2 fibrosis stages between LB 
and LSM was 0.21 rather than 0.3, which was used as the 
standard cutoff value for guaranteeing the reliability of LSM. 
These newly proposed and more stringent criteria of Lu-
cidarme, et al.7 narrowed the scope of previously consid-
ered reliable LSMs and led us to reconsider LSM results 
with IQR/M in a borderline range (from 0.21 to 0.3). In a 
study of Korean patients with CHB, Kim, et al.8 concluded 
VMs are obtained, more than 60% of measurements are 
successful,1,2 and the IQR/M is less than 0.3.5,6 The Fi-
broScan® manufacturer recommends these criteria; howev-
er, they are not based on scientific evidence. Investigators 
therefore have questioned their validity and influences on 
LSM accuracy.
In a study of European patients with CHC, Lucidarme, et 
al.7 concluded that the optimal IQR/M cutoff value to pre-
Table 4. Performance of LSM in Predicting Significant Fibrosis (≥F2) and Cirrhosis (F4) Using the First 3, the First 5, and All VMs 
Chronic hepatitis B (n=182) Chronic hepatitis C (n=68)
AUROC 95% CI AUROC 95% CI
Prediction of ≥F2
    Using the first 3 VMs 0.892 0.804-0.981 0.892 0.812-0.972
    Using the first 5 VMs 0.886 0.796-0.977 0.886 0.804-0.968
    Using all VMs 0.880 0.787-0.974 0.891 0.809-0.973
Prediction of F4
    Using the first 3 VMs 0.873 0.819-0.926 0.966 0.923-1.010
    Using the first 5 VMs 0.879 0.827-0.932 0.974 0.938-1.009
    Using all VMs 0.874 0.820-0.927 0.969 0.931-1.008
LSM, liver stiffness measurement; VMs, valid measurements; AUROC, area under the receiver operating characteristic curve; CI, confidence interval.
Fig. 2. The receiver operating characteristic curves using the first 3, the first 5, and all VMs for predicting significant fibrosis (≥F2) (A and C) and cirrhosis (F4) 
(B and D) in chronic hepatitis B (A and B) and C (C and D). The first 3, first 5, and all VMs taken significantly predicted fibrosis stages ≥F2 and F4 (all p<0.05) 
and AUROC values among the first 3, the first 5, and all VMs taken did not differ significantly (all p>0.05 by DeLong’s method
24). VMs, valid measurements. 
AUROC, area under the receiver operating characteristic curve.
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However, because the patients with more than 3 VMs, but 
less than 10 VMs comprised only about 5% of the study pop-
ulation, the authors could not link any patient characteristic 
to the number of VMs required. Furthermore, different prev-
alence in obesity and metabolic syndrome between Asian 
and Western populations as well as different viral character-
istics between CHB and CHC may significantly influence 
LSM results.16,21,25 Thus, the minimal number of VMs re-
quired in Asian patients with CHB or CHC should be in-
vestigated.
In contrast to previous studies, we found that LSM predict-
ed cirrhosis less accurately than it did significant fibrosis in 
patients with CHB. A potential spectrum bias, due to an ex-
tremely high prevalence of cirrhosis (more than 60%), might 
explain this finding.26 However, the performance of LSM in 
our study for patients with CHC agrees with literature values. 
In common with a previous study,9 we found that the accura-
cy of LSM in predicting significant fibrosis and cirrhosis us-
ing median elasticity scores from the first 3, first 5, and all 
VMs taken was similar in both patients with CHB and those 
with CHC. From this, we decided that 3 VMs of LSM may 
suffice in assessing liver fibrosis without significant loss of 
accuracy and then tried to identify factors that predict discor-
that neither success rate nor IQR/M was a predictive factor 
of the accuracy for diagnosing liver fibrosis and that the 
confounding effects of ALT might overshadow the influ-
ence of success rate and IQR/M on the accuracy of LSM. A 
recent study in Canada proposed that four factors, mild fi-
brosis, higher BMI, ALT, and IQR/M, are significantly re-
lated to discordance between LB and LSM, although etiol-
ogies of chronic liver disease were mixed.10 In all of these 
three studies, however, only patients with more than 10 VMs 
were enrolled; hence, the minimal number of VMs required 
for reliable LSM without significant loss in accuracy could 
not be analyzed. As a result, valid LSM results might have 
continually been discarded because of the overestimated 
standard number of VMs required for reliability of LSM. 
Thus, it is imperative to set the optimal number of VMs.
Fortunately, Kettaneh, et al.9 reported that the perfor-
mance in diagnosing significant fibrosis and cirrhosis using 
LSM was similar for whether one used the first 3, first 5 or 
all 10 VMs for calculating median elasticity scores in pa-
tients who underwent at least 10 VMs. From this study, they 
concluded that setting the number of VMs at 5 or more will 
extend the benefits from LSM to more European patients 
with CHC without significant loss of diagnostic accuracy. 
Table 5. Predictors of Discordance in Fibrosis Stage Estimated by the First 3 VMs and Liver Biopsy
Non-discordance* Discordance
† Univariate Multivariate
p value HR 95% CI p value
Chronic hepatitis B n=154 n=28
   Age (yrs)   47.1±11.1   40.0±12.7 0.004  0.995 0.955-1.037 0.805
   Male 102 (66.2) 21 (75.0) 0.437 
   BMI (kg/m
2) 23.4±2.7 23.5±3.3 0.898
   Albumin (g/dL)   4.2±0.6   4.6±0.4 0.004 3.942   0.995-15.094  0.055
   Total bilirubin (mg/dL)   0.9±1.1   1.0±1.6 0.662
   ALT (IU/L)   49.8±45.4   104.0±115.0 0.004  1.010  1.003-1.017 0.006 
   Platelet count (10
3/mm
3) 165.8±64.7 205.7±67.6 0.005  1.001  0.993-1.009 0.811
   Prothrombin time (%)   91.0±10.6 96.5±5.8 0.013  1.072 0.983-1.168 0.115 
   Spleen size (cm) 10.3±1.8 10.5±1.9 0.546 
Chronic hepatitis C n=64 n=4
    Age (yrs)   49.4±11.6   54.3±11.3 0.419 
    Male 25 (39.1) 2 (50.0) 0.704 
    BMI (kg/m
2) 22.9±3.0 25.1±5.6 0.198 
    Albumin (g/dL)   4.4±0.3   4.2±0.7 0.382 
    Total bilirubin (mg/dL)   0.7±0.3   1.4±0.9 0.015  8.297      0.658-104.574  0.102 
    ALT (IU/L)   50.7±58.9   92.5±68.4 0.213 
    Platelet count (10
3/mm
3) 202.6±63.7 187.3±85.0 0.644 
    Prothrombin time (%) 98.0±5.5   89.3±18.3 0.050  1.007  0.870-1.166  0.921 
    Spleen size (cm)   9.3±1.4 11.1±1.4 0.041  1.613  0.812-3.203  0.172 
VMs, valid measurements; HR, hazard ratio; CI, confidence interval; BMI, body mass index; ALT, alanine aminotransferase; LB, liver biopsy. 
Variables are expressed as the mean±SD or n (%).
Non-discordance* indicates that fibrosis stage estimations using the first 3 VMs and LB agree. If not, the estimations are categorized as discordant
†.Hui Won Jang, et al.
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the first 3 VMs for LSM.
As in Kettaneh, et al.,9 we compared the performance of 
the median elasticity scores from the first 3, first 5, and all 
VMs taken in patients with at least 10 VMs. This approach 
was unavoidable; however, as only 9 (3.2%) of the patients 
had fewer than 10 VMs before the exclusions in our study. 
Indeed, a sufficient number of patients with fewer than 10 
VMs should be assembled to identify baseline factors for 
predicting those who would or would not obtain more than 
10 VMs, by comparing their baseline characteristics before 
LSM examinations. Knowledge of these baseline predictors 
will allow us to decide when to stop measuring further un-
necessary measurements of liver elasticity, allowing us to 
use only the minimal, but sufficient number of VMs for 
each patient. Furthermore, doing so will eventually clarify 
whether a reduced number of VMs of less than 10 can be 
adopted for analyzing the performance of LSM in an ade-
quate study group with less than 10 VMs available. In our 
study, a small number of patients with than 10 VMs is one 
of our main limitations. A larger study, possibly a multi-cen-
ter trial, including patients with a strategic balance of VMs 
should be performed to justify our findings. In addition, the 
small sample size overall, especially for patients with CHC, 
is another limitation of our study. Finally, we used external 
studies on the performance of LSM in Asian patients as ref-
erence cutoff values. Therefore, results of this study might 
be not relevant for Europeans.
In conclusion, three VMs may be enough to assess liver 
fibrosis using LSM without significant loss of accuracy in 
patients with CHB and patients with CHC. However, ALT 
should be considered in the interpretation of LSM results 
for patients with CHB.
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